Overview

Ipilimumab is a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), an immune checkpoint expressed on the surface of early-activated T cells. The core mechanism is that CTLA-4 normally competes with CD28 for B7 ligands and applies a brake on priming, so removing that brake lets naive T cells expand against tumor antigens. Supplied as a 50 mg/10 mL concentrate for solution for infusion, it is a Bristol Myers Squibb origin biologic used across several advanced tumors. Because it acts during the priming phase in lymphoid tissue, the antibody reshapes the breadth of the antitumor T-cell pool rather than merely reactivating cells already at the tumor.

How It Works

By binding CTLA-4 with high affinity, Ipilimumab prevents the receptor from docking onto B7-1 and B7-2 costimulatory molecules on antigen-presenting cells. This restores the CD28 costimulatory signal that T cells need during initial activation in lymph nodes. Unlike antibodies that act at the tumor interface, CTLA-4 blockade works upstream, broadening the repertoire of primed T-cell clones. The effect is qualitatively distinct from PD-1 axis inhibition, which mainly reinvigorates T cells already infiltrating tissue. This early-node action also explains the characteristic timing of immune-related adverse events, which often emerge weeks after dosing as newly primed clones encounter normal tissue.

Indications

Ipilimumab is used in unresectable or metastatic melanoma, and in combination strategies for renal cell carcinoma, microsatellite-stable colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, and malignant pleural mesothelioma. Selection depends on the intended regimen and the treating center's sequencing plan. B2B buyers should confirm the presentation matches the local registration status. In practice the agent is rarely used as a standalone infusion in modern protocols; it is embedded within combination regimens where its priming effect complements a PD-1 partner.

Dosage & Administration

Dosing follows a weight-based calculation delivered as an intravenous infusion, typically administered over a defined minutes-long period rather than a rapid push. Combination schedules with a PD-1 antibody use staggered timing to manage overlapping immune events. Each 50 mg/10 mL vial supports precise dose preparation under aseptic conditions and is drawn up only at the point of administration.

Storage & Sourcing

Keep Ipilimumab refrigerated at 2 to 8°C and protect from light; do not freeze. As a monoclonal antibody, supply depends on validated cold-chain handling and batch release documentation. Procurement teams should track serial numbers and expiry to preserve product integrity during transit. Light-protected refrigerated transport preserves the antibody's structural integrity across long distribution routes.

FAQ

Q: How does CTLA-4 blockade differ from PD-1 blockade mechanistically? A: CTLA-4 blockade acts early in lymphoid tissue to broaden T-cell priming, whereas PD-1 blockade mainly restores function of T cells already inside the tumor.

Q: Why is the Ipilimumab infusion spread over minutes rather than a rapid push? A: A controlled infusion rate limits acute infusion reactions and supports safe observation for immune-related adverse events during administration.

Q: Which immune-related adverse events stem from CTLA-4 priming? A: Enteritis, hepatitis, and dermatitis are among the events linked to broad T-cell activation, requiring baseline and periodic organ-function monitoring.